Our new INSIGHTS paper, “Investing into extracellular vesicle-based diagnostic and therapeutics. Uncovering the opportunities, challenges, and restraints in the emerging markets.” is live.
Exosome-based diagnostics and therapeutics have the potential to represent a long-awaited paradigm shift in the healthcare sector. With investments into exosome-based products and technologies projected to reach several billion USD by the decade’s end, the exosome-based diagnostics market has seen some exciting developments in recent years. At the same time, there is still no FDA-approved exosome-based therapy on the market.
We have identified some key drivers that would promote further growth. We also delve into the challenges that these markets may face. Finally, we examine the various restraints that still affect the development of these markets.
Understanding these factors is crucial for investors considering investing in the exosome-based diagnostics and therapeutics markets. Use the form below to access it.
INSIGHTS03 (pdf, new tab)
